Acetylon Pharmaceuticals’s Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th American Society of Hematology Annual Meeting And Exposition

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that ricolinostat, the Company’s lead selective HDAC6 inhibitor, and selective HDAC1/2 inhibitors will be featured in one oral presentation and five posters at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2014, in San Francisco, CA.

Help employers find you! Check out all the jobs and post your resume.